Prize bestowed to Dr. Zhijian “James” Chen for discovery of the cGAS enzyme and its DNA-sensing pathway and their impact on immune defense and autoimmune disease.
The Foundation for the National Institutes of Health (FNIH) is pleased to open nominations for the inaugural Trailblazer Prize for Clinician-Scientists (Trailblazer Prize). This annual prize and $10,000 honorarium presented by the FNIH recognizes the outstanding contributions of early career clinician-scientists in the United States whose work has the potential to or has led to innovations in patient care. To nominate a colleague for this prize and learn about eligibility criteria, visit fnih.org/TrailblazerPrize. Nominations will be accepted through Friday, March 30 at 1:00 p.m. ET.
The Foundation for the National Institutes of Health (FNIH) is proud to announce that it received the Gold Stevie Award for Organization of the Year in the government/nonprofit category of the Women in Business Awards. The FNIH’s President and Executive Director, Maria C. Freire, Ph.D., also received a Gold Stevie Award for Woman of the Year in the government/non-profit category.
The Foundation for the National Institutes of Health (FNIH) is proud to announce that President and Executive Director Maria C. Freire, Ph.D. has won a Washington Business Journal Women Who Mean Business Award. Now in its 14th year, this prestigious award honors the Washington, D.C. metropolitan area’s most influential business women across every industry and profession.
The Board of Directors of the Foundation for the National Institutes of Health (FNIH) has unanimously elected Fred Seigel as a new member. Mr. Seigel is President and Chief Operating Officer of Beacon Capital Partners, a private real estate investment company based in Boston.
The Foundation for the National Institutes of Health (FNIH) has selected David M. Sabatini, M.D., Ph.D., to receive its fifth annual Lurie Prize in Biomedical Sciences for discovery of the mTOR (mechanistic target of rapamycin) cellular pathway as a key regulator of growth and metabolism in response to nutrients. Dr. Sabatini is a pioneer in the study of nutrient sensing and the impact of caloric restriction on health and lifespan. The Lurie Prize in Biomedical Sciences will be presented to Dr. Sabatini at the FNIH Award Ceremony hosted by CNN’s Wolf Blitzer on May 17 in Washington, D.C.
Driven to Cure, Inc., a not-for-profit dedicated to raising awareness and funding rare kidney cancer research in children and young adults, has donated $200,000 to the Foundation for the National Institutes of Health (FNIH). The donation will support the research of W. Marston Linehan, M.D., Chief of Urologic Surgery and the Urologic Oncology Branch, Center for Cancer Research, at the National Cancer Institute (NCI), who is developing novel approaches to treat multiple forms of kidney cancer.
The Foundation for the National Institutes of Health (FNIH) has selected two longstanding, private-sector partners — Bill & Melinda Gates Foundation and Pfizer — as recipients of the inaugural Charles A. Sanders, M.D., Partnership Award. Honoring 20 years of advancing biomedical research under the leadership of former Chairman of the Board Charles A. Sanders, M.D., the award recognizes persons and/or organizations that have made significant contributions to the FNIH’s work to build, implement and nurture private-public partnerships in support of the mission of the National Institutes of Health (NIH).
The Foundation for the National Institutes of Health (FNIH) announces that patient advocacy groups, private foundations, companies and individual donors have again united in the fight against Alzheimer’s disease by donating more than $14 million to launch the third phase of the Alzheimer’s Disease Neuroimaging Initiative (ADNI3). Now in its 12th year, this public- private partnership with the National Institutes of Health (NIH) has profoundly influenced the understanding of Alzheimer’s disease by identifying and validating biological markers (biomarkers) that signal its onset and progression. Current supporters of ADNI3 are AbbVie, Alzheimer’s Association, Bioclinica, Biogen, Cogstate, DiamiR Biosciences, Eisai, Genentech (a member of the Roche Group), Janssen R&D, LLC, Lundbeck, Merck & Company, Inc., PeopleBio, Inc., Pfizer, Inc., Roche, Servier and Takeda. The FNIH anticipates raising a total of $20 million to fund the project.